|Bid||41.14 x 1400|
|Ask||41.25 x 3100|
|Day's range||41.11 - 41.66|
|52-week range||31.43 - 48.25|
|Beta (5Y monthly)||0.42|
|PE ratio (TTM)||41.54|
|Earnings date||01 Feb 2017 - 06 Feb 2017|
|Forward dividend & yield||1.89 (4.58%)|
|Ex-dividend date||14 May 2020|
|1y target est||47.70|
GSK's belantamab mafodotin, or BLENREP, was approved for treating adults with relapsed and refractory multiple myeloma who no longer respond to treatment with an immunomodulatory agent, the drugmaker said in a statement. Multiple myeloma is the second most common form of blood cancer in the U.S. and is generally considered treatable, but not curable. A U.S. FDA panel had earlier raised safety concerns about the drug causing deposits to gather on the cornea in the eyes, but later voted in its favor saying the benefits of the treatment outweigh the risks.
FDA Approves GSK’s BLENREP (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.
The Zacks Analyst Blog Highlights: Eli Lilly, Moderna, Pfizer, Sanofi, GlaxoSmithKline and BioNTech